QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,580 signal articles · 330 in last 24h · 112,379 total before filter · latest 46m ago
330last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
AllMacro294Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: PMSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Philip Morris (NYSE:PM) Surprises With Q2 CY2026 Sales
StockStory21d agoneutral
Philip Morris (NYSE:PM) Surprises With Q2 CY2026 Sales

Tobacco company Philip Morris International (NYSE:PM) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.4% year on year to $11.19 billion. Its GAAP profit of $1.80 per share was 9% below analysts’ consensus estimates.

How To Earn $500 A Month From Philip Morris Stock Ahead Of Q2 Earnings
Benzinga21d agoneutral
How To Earn $500 A Month From Philip Morris Stock Ahead Of Q2 Earnings

Philip Morris International Inc‘s (NYSE:PM) investors may be eyeing potential gains from the tobacco company’s dividends ahead of its second-quarter earnings report on Wednesday, July 22. Analysts expect quarterly earnings of $2.05 per share, up from $1.91 per share in...

Philip Morris International (PM) Is Up 6.3% After FDA Grants ZYN Modified Risk Status - Has The Bull Case Changed?
Simply Wall St.26d agoneutral
Philip Morris International (PM) Is Up 6.3% After FDA Grants ZYN Modified Risk Status - Has The Bull Case Changed?

Earlier this week, Philip Morris International announced that the U.S. FDA had authorized commercialization of its ZYN smoke-free nicotine pouches as modified risk tobacco products, recognizing that switching completely from cigarettes to ZYN reduces exposure to harmful chemicals linked to major smoking-related diseases. This decision makes ZYN the first and only nicotine pouch brand with modified risk status in the U.S., giving Philip Morris a distinct regulatory and scientific edge in the...

Is Philip Morris International (PM) Fully Valued On ZYN FDA Authorization?
Simply Wall St.26d agoneutral
Is Philip Morris International (PM) Fully Valued On ZYN FDA Authorization?

Philip Morris International (PM) is back in focus after the U.S. Food and Drug Administration authorized its ZYN smoke free nicotine pouches as modified risk tobacco products, marking the first such authorization for the nicotine pouch category. See our latest analysis for Philip Morris International. Philip Morris International’s recent FDA milestone comes on top of strong share price momentum, with a 22.30% 90 day share price return and a 147.74% five year total shareholder return,...